Progress of mesenchymal stem cell-derived exosomes in targeted delivery of antitumor drugs.

IF 5.3 2区医学 Q1 ONCOLOGY

Cancer Cell International Pub Date : 2025-04-29 DOI:10.1186/s12935-025-03795-x

Defa Huang, Wenlong Huang, Meijin Liu, Jie Chen, Dewang Xiao, Zongbo Peng, Haoquan He, Haibin Shen, Qing Jin, Linli Chen, Dingyu Rao, Minghong Zhao, Junyun Huang

{"title":"Progress of mesenchymal stem cell-derived exosomes in targeted delivery of antitumor drugs.","authors":"Defa Huang, Wenlong Huang, Meijin Liu, Jie Chen, Dewang Xiao, Zongbo Peng, Haoquan He, Haibin Shen, Qing Jin, Linli Chen, Dingyu Rao, Minghong Zhao, Junyun Huang","doi":"10.1186/s12935-025-03795-x","DOIUrl":null,"url":null,"abstract":"<p><p>Mesenchymal stem cells (MSCs) are currently being used in clinical trials for the treatment of a wide range of diseases and have a wide range of applications in the fields of tissue engineering and regeneration. Exosomes are extracellular vesicles containing a variety of components such as proteins, nucleic acids and lipids, which are widely present in biological fluids and have the functions of participating in intercellular information transfer, immune response and tissue repair, and can also be used as carriers to target and deliver tumors to improve therapeutic effects. Mesenchymal stem cell-derived Exosomes (MSC-Exos), which have the advantages of low immunogenicity and high tumor homing ability, have attracted much attention in targeted drug delivery. Here, we review the current knowledge on the involvement of MSC-Exos in tumor progression and their potential as drug delivery systems in targeted therapies. It also discusses the advantages and prospects of MSC-Exos as a drug carrier and the challenges that still need to be overcome.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"169"},"PeriodicalIF":5.3000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042352/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12935-025-03795-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Mesenchymal stem cells (MSCs) are currently being used in clinical trials for the treatment of a wide range of diseases and have a wide range of applications in the fields of tissue engineering and regeneration. Exosomes are extracellular vesicles containing a variety of components such as proteins, nucleic acids and lipids, which are widely present in biological fluids and have the functions of participating in intercellular information transfer, immune response and tissue repair, and can also be used as carriers to target and deliver tumors to improve therapeutic effects. Mesenchymal stem cell-derived Exosomes (MSC-Exos), which have the advantages of low immunogenicity and high tumor homing ability, have attracted much attention in targeted drug delivery. Here, we review the current knowledge on the involvement of MSC-Exos in tumor progression and their potential as drug delivery systems in targeted therapies. It also discusses the advantages and prospects of MSC-Exos as a drug carrier and the challenges that still need to be overcome.

查看原文本刊更多论文

间充质干细胞来源的外泌体靶向递送抗肿瘤药物的研究进展。

间充质干细胞（Mesenchymal stem cells, MSCs）目前被广泛应用于临床试验，用于治疗多种疾病，在组织工程和再生领域有着广泛的应用。外泌体是含有蛋白质、核酸、脂质等多种成分的细胞外囊泡，广泛存在于生物体液中，具有参与细胞间信息传递、免疫应答和组织修复等功能，也可作为载体靶向传递肿瘤，提高治疗效果。间充质干细胞源性外泌体（MSC-Exos）具有低免疫原性和高肿瘤归巢能力等优点，在靶向药物递送领域受到广泛关注。在这里，我们回顾了目前关于MSC-Exos参与肿瘤进展及其作为靶向治疗药物传递系统的潜力的知识。讨论了MSC-Exos作为药物载体的优势和前景，以及仍需克服的挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell International ONCOLOGY-

CiteScore

10.90

自引率

1.70%

发文量

360

审稿时长

1 months

期刊介绍： Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques. The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors. Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.